InvestorsHub Logo
Followers 157
Posts 6403
Boards Moderated 1
Alias Born 08/06/2004

Re: None

Tuesday, 08/24/2021 10:23:31 AM

Tuesday, August 24, 2021 10:23:31 AM

Post# of 468874
Time wise, SAVA is 'YEARS' behind AVXL which is already and currently in a AD Ph-2b/3.

SAVA new this morning:

The first clinical study protocol under the SPA is titled “A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 52-Week Study Evaluating the Safety and Efficacy of One Dose of Simufilam in Subjects with Mild-to-Moderate Alzheimer's Disease”.

The second clinical study protocol under the SPA is titled “A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 76-Week Study Evaluating the Safety and Efficacy of Two Doses of Simufilam in Subjects with Mild-to-Moderate Alzheimer’s Disease”.

https://finance.yahoo.com/news/cassava-sciences-announces-agreement-fda-121500823.html

Not mentioned is how long the recruiting the trial patients will take, and that will take substantial time.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News